Category Archives: Doctrine of equivalents

Rejected claim construction proposal during IPR was not prosecution history estoppel, FC affirms infringement under DOE; second infringement decision reversed

Galderma Labs., Nestle Skin Health S.A. et al. v. Amneal Pharm. LLC et al. Docket No. 2019-1021 LOURIE, MOORE, STOLL March 25, 2020 Non-Precedential Brief Summary: DC finding of infringement of certain claims affirmed as statements made in related IPR … Continue reading

Posted in Claim Construction, Doctrine of equivalents, Infringement, Inter Parties Review (IPR), IPR, Prosecution History Estoppel, Uncategorized | Leave a comment

DC grant of SJ of no literal or DOE infringement affirmed

Plastic Omnium Advanced Innovation and Research v. Donghee America, Inc. et al. Docket Nos. 2018-2087 NEWMAN, CLEVENGER, REYNA December 3, 2019 Brief Summary: DC grant of SJ of no literal infringement or under the DOE affirmed based on DC claim … Continue reading

Posted in Claim Construction, Doctrine of equivalents, Infringement, Uncategorized | Leave a comment

Infringement of analyte measurement device claims under DOE barred by prosecution history estoppel

Pharma Tech Solutions, Inc. et al. v. LifeScan, Inc. (Johnson and Johnson) Docket Nos. 2019-1163 MOORE, REYNA, STOLL November 22, 2019 Brief Summary: DC grant of SJ of no infringement under DOE affirmed due to prosecution history estoppel. Summary: Pharma … Continue reading

Posted in Doctrine of equivalents, Infringement, Prosecution History Estoppel, Uncategorized | Leave a comment

Lilly’s Orange Book ‘209 patent regarding administration of pemetrexed not literally infringed, but infringed under DOE

Eli Lilly and Company v. Hospira, Inc., Dr. Reddy’s Laboratories Docket No. 2018-2126, -2127, -2128 LOURIE, MOORE, TARANTO August 9, 2019 Brief Summary: DC literal infringement decision reversed, but infringement under DOE affirmed. Summary: Hospira and Dr. Reddy’s (DRL) appealed … Continue reading

Posted in Claim Construction, Doctrine of equivalents, Generics / ANDA, Infringement, Method claims, Prosecution History Estoppel, Uncategorized | Leave a comment

ITC claim construction, written description, and finding of infringement by imported E. coli strains affirmed by Federal Circuit

Ajinomoto Co. et al. v. Int. Trade Commission (ITC) et al. Docket No. 2018-1590, -1629 (ITC No. 337-TA-1005) DYK (C/D), MOORE, TARANTO August 6, 2019 Brief Summary: ITC claim construction, written description, and finding that certain E. coli strains imported … Continue reading

Posted in Claim Construction, Doctrine of equivalents, Importation, Infringement, International Trade Commission, Prosecution History Estoppel, Uncategorized, Written description | Leave a comment

DC decision that Invidior’s Suboxone® sublingual film patents are infringed by certain parties and not invalid for obviousness affirmed

Invidior Inc. et al. v. Dr. Reddy’s Labs. (DRL), Actavis/Watson, Teva, Par, Intelgenx, Alvogen Pine Brook, LLC Docket Nos. 2017-2587, 2018-1010, -1058, -1062, -1114, -1115, -1176, -1177 Newman, Mayer (D), Lourie July 12, 2019 Brief Summary: DC findings that Invidior … Continue reading

Posted in Claim Construction, Doctrine of equivalents, Generics / ANDA, Obviousness, Written description | Leave a comment

Amgen, Inc. et al. v. Sandoz Inc. et al.

Docket Nos. 2018-1551 and -1552 LOURIE, O’MALLEY, REYNA May 8, 2019 Brief summary: DC claim construction findings and grant of SJ of non-infringement to Sandoz regarding its Neupogen® and Neulasta® biosimilars affirmed. Summary: Amgen appealed two DC decisions finding Sandoz’s … Continue reading

Posted in Biosimilars, Claim Construction, Collateral estoppel, Doctrine of equivalents, Generics / ANDA, Infringement | Leave a comment